Wegovy (semaglutide) is a once-weekly injectable GLP-1 receptor agonist made by Novo Nordisk, FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related condition, and for cardiovascular risk reduction in adults with established heart disease who are overweight or obese. Insurers deny Wegovy prior authorization requests more often than almost any other GLP-1 drug because plans require documented proof that a patient meets the BMI and comorbidity thresholds, has tried lifestyle intervention, and in many cases has failed a cheaper step-therapy alternative first.
Medicare Part D enrollees face an additional layer: Medicare has historically excluded weight-loss-only drugs by statute, so a Wegovy denial from a Part D plan may cite that exclusion even when the patient qualifies under the newer cardiovascular-risk-reduction indication or the Medicare GLP-1 Bridge demonstration running July 1, 2026 through December 31, 2027. Semaglutide (covering Ozempic, Wegovy, and Rybelsus) was also selected for the second round of Medicare drug price negotiation under the Inflation Reduction Act; the negotiated Maximum Fair Price of approximately $274 per month does not take effect until January 1, 2027, so it has no bearing on a 2026 denial or appeal.
Novo Nordisk built a formal appeal support system for exactly this problem: sample appeal letters, a prior authorization criteria checklist, and a peer-to-peer review request process available through NovoMedLink and NovoCare. Patients who exhaust both appeal levels are not left without options; the Novo Nordisk Patient Assistance Program and the $349 per month NovoCare Pharmacy self-pay channel remain available regardless of insurance denial status. For the standalone cost breakdown by coverage type, see the Wegovy cost guide; for the diabetes-labeled version of the same molecule, see Ozempic cost.
What Wegovy Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same wegovy can cost many times more at a hospital than at your local pharmacy:
2026 Wegovy Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail pharmacy counter (cash, GoodRx coupon) | $1,229 - $1,419/month | 2026 price while a prior authorization appeal is pending; varies by chain and coupon routing |
| NovoCare Pharmacy (self-pay, no insurance) | $349/month | Manufacturer-direct fallback if your appeal is denied or still pending; no prior authorization required |
| Medicare Part D (after a successful appeal) | $50/month (GLP-1 Bridge) or formulary tier cost up to the $2,100/year cap | GLP-1 Bridge runs July 1, 2026 through December 31, 2027 for BMI 27+ with a qualifying condition |
| Commercial insurance (after a successful appeal) | $25 - $650/month depending on formulary tier | NovoCare Savings Card can bring approved copays down to $25/month |
| Medicaid | $1 - $10/month, with prior authorization | About 38 states cover GLP-1s for obesity as of 2026; denial and fair-hearing appeal rules vary by state |
Prices reflect 2026 GoodRx pharmacy surveys and Novo Nordisk manufacturer programs. Costs after a successful appeal depend on your plan's formulary tier and where you are in the Part D benefit year.
Source: GoodRx 2026 pharmacy pricing; CMS Medicare GLP-1 Bridge; NovoCare Savings Card and Patient Assistance Program terms
Why Hospitals Charge So Much
Wegovy is a self-injected outpatient drug that patients administer at home once weekly, so it rarely triggers inpatient hospital billing. The exception arises when a hospitalized patient continues therapy during an admission and the hospital dispenses or administers a dose; in that scenario, facility markups of two to four times the retail rate are common.
Hospital pharmacies frequently lack a dedicated HCPCS code for Wegovy and instead bill it under the miscellaneous J3490 code (Drug, Not Otherwise Classified). Insurers sometimes deny that miscellaneous code automatically unless the hospital attaches a National Drug Code and a clinical justification narrative, which produces a second, unrelated denial layered on top of any outpatient prior authorization dispute a patient is already fighting.
Patients who bring their own Wegovy pen into a hospital stay should watch for duplicate charges. Request an itemized bill, compare any Wegovy line item to the $349 per month NovoCare Pharmacy cash price, and dispute any charge above $1,400 for a single monthly supply through your hospital's billing office or the CoveredUSA Medical Bill Analyzer.
Patient Assistance Programs
Novo Nordisk operates three cost-relief pathways for Wegovy, and the right one depends on whether your prior authorization appeal succeeds, is still pending, or has been permanently denied.
Patient assistance programs for Wegovy| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Savings Card (commercially insured, PA approved) | As low as $25/month for up to 12 months once your commercial plan approves Wegovy. No income limit. | novocare.com/patient/medicines/wegovy/savings-offer.html |
| NovoCare Pharmacy (self-pay, no insurance or appeal pending) | $349/month for standard approved doses, shipped directly, no prior authorization required | novocare.com/patient/medicines/wegovy.html |
| Novo Nordisk Patient Assistance Program (permanently denied or uninsured) | Free Wegovy for eligible patients with household income at or below 400% of the federal poverty level | novocare.com/pap |
Manufacturer coupons and savings cards, including the NovoCare Savings Card, cannot be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under the federal anti-kickback statute (42 U.S.C. 1320a-7b). Medicare enrollees denied Wegovy should pursue the appeal process, the Medicare GLP-1 Bridge, or the income-based Patient Assistance Program instead of a manufacturer coupon.
Source: NovoCare.com, NovoMedLink.com, NeedyMeds.org
Medicare Part D
Medicare Part D plans may cover Wegovy in 2026 only when a prescriber documents the FDA cardiovascular risk-reduction indication (established heart disease plus overweight or obesity) or, starting July 1, 2026, through the Medicare GLP-1 Bridge demonstration for enrollees with a BMI of 27 or above and a qualifying condition. Plans routinely deny Wegovy for weight loss alone, which is the single most common reason Medicare beneficiaries end up appealing.
Medicare beneficiaries who receive a Part D denial have 65 days from the date on the denial notice to request a Level 1 appeal, called a redetermination, directly from their Part D plan. If the plan upholds the denial, the enrollee has 60 days to request a Level 2 Reconsideration from an independent Qualified Independent Contractor. Prescribers can request an expedited redetermination, decided within 72 hours, when a standard 7-day timeline would seriously jeopardize the patient's health.
The $50 GLP-1 Bridge copay and a standard formulary copay after a successful appeal interact with the $2,100 annual Part D out-of-pocket cap differently: the Bridge copay does not count toward the cap, while a standard formulary tier copay does count. Confirm with your Part D plan which pathway applies to your case before assuming how an appeal win affects your annual cap math.
Common Wegovy Billing Errors
Patients who win a Wegovy prior authorization appeal, or who fall back to self-pay while an appeal is pending, should watch for these billing problems:
- Pharmacy still processing the claim under the original denial after a successful appeal, causing the patient to be charged the full $1,229 to $1,419 cash price instead of the approved copay.
- NovoCare Savings Card not applied at the counter due to a processor error after PA approval, leaving the patient to pay hundreds of dollars above the $25 cap.
- Medicare Part D plan skipping the required 65-day redetermination notice period and closing the appeal file early.
- Hospital billing the miscellaneous code J3490 for Wegovy without the required National Drug Code narrative, triggering an automatic denial unrelated to the outpatient prior authorization appeal.
- Pharmacy billing the $50 GLP-1 Bridge copay toward the Part D deductible or the $2,100 annual out-of-pocket cap, when it should count toward neither.
- Medicaid managed care plan continuing to apply step therapy requirements after a fair hearing already overturned the original denial.
Frequently Asked Questions
Is there a generic or biosimilar version of Wegovy?
No generic or biosimilar semaglutide is approved for retail sale in 2026. Novo Nordisk's patent exclusivity for Wegovy runs to approximately 2031. Ozempic and Rybelsus contain the same semaglutide molecule but carry separate FDA labels for type 2 diabetes and different prior authorization criteria, so switching between them does not bypass a Wegovy denial. Compounded semaglutide is largely unavailable since the FDA removed it from the drug shortage list in 2024.
How do I apply for the Novo Nordisk patient assistance program for Wegovy?
Start at novocare.com/pap or call 1-888-809-3942. Complete the patient section of the application while your prescriber completes the provider section, then submit proof of household income, proof of US residency, and your current Wegovy prescription. Attach your insurance denial letter if you have one. Processing typically takes 1 to 2 weeks, and approved patients receive Wegovy shipped directly at no cost, with annual reapplication required.
Can I use the NovoCare savings card with Medicare?
No. Federal anti-kickback law bars manufacturer coupons and savings cards, including the NovoCare Savings Card, from Medicare, Medicaid, TRICARE, and VA beneficiaries. If you have Medicare and your Wegovy claim was denied, pursue the Medicare Part D redetermination appeal process, the Medicare GLP-1 Bridge program, or the income-based Patient Assistance Program instead.
What do I do if my insurance denies coverage for Wegovy?
Request the written denial notice and confirm the exact reason and appeal deadline. Medicare Part D enrollees have 65 days to request a redetermination; commercially insured patients typically have 180 days for an internal appeal. Ask your prescriber to submit a medical necessity letter with BMI history and comorbidities, and request a peer-to-peer review with the plan's medical director. If the first appeal fails, Medicare enrollees get an automatic Reconsideration, and commercial patients can request an external review through their state Department of Insurance. Well-documented prior authorization appeals succeed at high rates when they include complete clinical history.
Does the Inflation Reduction Act's negotiated price apply to Wegovy in 2026?
Not yet. Semaglutide (Ozempic, Wegovy, and Rybelsus) was selected for the second round of Medicare drug price negotiation under the Inflation Reduction Act. The negotiated Maximum Fair Price of approximately $274 per month takes effect January 1, 2027, not 2026. Until then, Medicare beneficiaries pay standard Part D formulary tier costs, the $50 GLP-1 Bridge copay if eligible, or costs that count toward the general $2,100 annual Part D out-of-pocket cap.
What does Wegovy cost without insurance at the pharmacy counter in 2026?
Cash and GoodRx coupon prices in 2026 range from about $1,229 per month at Costco to $1,419 per month at CVS for a 28-day supply, with Walmart, Kroger, and Walgreens falling in between. Novo Nordisk's own NovoCare Pharmacy offers a manufacturer-direct self-pay option starting at $349 per month for standard approved doses, which is usually the cheapest legitimate cash option while a prior authorization appeal is pending.
Do I qualify for the Novo Nordisk patient assistance program for Wegovy?
You generally qualify if your household income is at or below 400 percent of the federal poverty level, you are a US resident, you have a valid Wegovy prescription, and you either lack prescription drug coverage or your plan does not cover Wegovy. For a household of 4 in 2026, 400 percent of the federal poverty level is $132,000 per year. The program does not require an approved prior authorization from your insurer, so it works even after a permanent denial.
Why was I approved for Ozempic but denied for Wegovy?
Ozempic and Wegovy both contain semaglutide, but they carry different FDA labels and different Medicare and commercial insurance rules. Ozempic is approved for type 2 diabetes, a condition most plans cover without a weight-based BMI threshold. Wegovy is approved for chronic weight management and, since March 2024, cardiovascular risk reduction; plans apply stricter prior authorization criteria, including BMI thresholds and documented comorbidities, and Medicare specifically excludes weight-loss-only use. A denial for Wegovy does not mean Ozempic will also be denied, and vice versa.
